Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

Author(s):

Marwan G. Fakih, MD, City of Hope,Nilo Azad, MD

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

EP: 1.Navigating mCRC: Treatment Options in the Third-Line Setting

EP: 2.Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Now Viewing

EP: 3.Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP: 4.Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP: 5.Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP: 6.Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP: 7.Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP: 8.Unmet Needs in Third-Line mCRC: Challenges and Opportunities

How do you take into account your patient’s preference and/or lifestyle when selecting from these treatment options? What is your approach to shared decision-making?
Is there an optimal sequence in which you give these potential treatment options? Dr Fakih, please also feel free to share your clinical perspective on treatment sequencing.